| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
730.81(B) |
| Last
Volume: |
1,955,966 |
Avg
Vol: |
3,290,337 |
| 52
Week Range: |
$423.21 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
220,750 |
870,750 |
2,710,260 |
6,211,418 |
| Total Sell Value |
$171,350,547 |
$608,250,580 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
3 |
13 |
42 |
89 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Johnson Kimberly H |
Director |
– • – |
2022-11-21 |
4 |
A |
$361.17 |
$189,614 |
D/D |
525 |
1,922 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-11-21 |
4 |
A |
$361.17 |
$129,660 |
D/D |
359 |
536 |
|
- |
|
| Kaelin William G Jr |
Director |
– • – |
2022-11-21 |
4 |
A |
$361.17 |
$179,863 |
D/D |
498 |
20,470 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-11-07 |
4 |
S |
$362.30 |
$23,141,044 |
D/D |
(63,585) |
103,158,810 |
|
9% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-11-04 |
4 |
S |
$362.26 |
$485,996 |
D/D |
(1,336) |
103,222,395 |
|
7% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-11-03 |
4 |
S |
$362.08 |
$48,499,892 |
D/D |
(133,948) |
103,223,731 |
|
9% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-11-02 |
4 |
S |
$362.07 |
$2,219,851 |
D/D |
(6,131) |
103,357,679 |
|
7% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-21 |
4 |
S |
$335.27 |
$54,786,634 |
D/D |
(161,936) |
103,363,810 |
|
9% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-19 |
4 |
S |
$335.48 |
$1,189,933 |
D/D |
(3,547) |
103,525,746 |
|
3% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-18 |
4 |
S |
$333.53 |
$4,022,377 |
D/D |
(12,042) |
103,529,293 |
|
6% |
|
| Alvarez Ralph |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$11,314 |
D/D |
34 |
52,002 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$9,983 |
D/D |
30 |
69,837 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$13,976 |
D/D |
42 |
14,085 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$9,650 |
D/D |
29 |
1,397 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$9,983 |
D/D |
30 |
1,029 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-10-17 |
4 |
A |
$332.76 |
$9,983 |
D/D |
30 |
177 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-17 |
4 |
S |
$333.76 |
$26,706,632 |
D/D |
(79,624) |
103,541,335 |
|
6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-14 |
4 |
S |
$333.75 |
$1,064,307 |
D/D |
(3,187) |
103,620,959 |
|
6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-12 |
4 |
S |
$333.50 |
$133,400 |
D/D |
(400) |
103,624,146 |
|
1% |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2022-10-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
450 |
6,500 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2022-10-10 |
4 |
AS |
$326.23 |
$214,007 |
D/D |
(656) |
6,950 |
|
2% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-10-06 |
4 |
S |
$333.89 |
$49,934,082 |
D/D |
(149,264) |
103,624,546 |
|
1% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-09-28 |
4 |
S |
$332.86 |
$34,053,650 |
D/D |
(101,631) |
103,773,810 |
|
-2% |
|
| Luciano Juan R |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$14,034 |
D/D |
46 |
14,043 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$10,068 |
D/D |
33 |
69,807 |
|
- |
|
1437 Records found
|
|
Page 11 of 58 |
|
|
6.28 (0.83%) 
